CSE PREV
LAST 0.58
CHANGE 0.08
OTC PRVCF
FSE 18H
CSE: PREV
LAST: 0.58
CHANGE: 0.08
OTC: PRVCF
FSE: 18H
Download as PDF  

Preveceutical Announces the Launch of CELLB9™, a Blue Scorpion Venom Based Serum Supporting Improved Wellness

Vancouver, British Columbia, June 1, 2016 – Preveceutical Medical Inc. ("Preveceutical", or the "Company"), a health and wellness company focused on combining nature and science for the benefit of health conscious consumers, is pleased to announce that CELLB9™ is now available for sale.

CELLB9™ is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide, obtained from Blue Scorpion serum. The active potentiated ingredients, in the Blue Scorpion serum appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colorless and odorless and can be administered orally.

“CELLB9™ and other products developed from Blue Scorpion Venom and Polarization Technology will form a strong set of related products for the Company,” said Stephen Van Deventer, Chairman and CEO at Preveceutical. “We are presently negotiating national distribution agreements on a country-by-country basis for the sale of CELLB9™, and will be pursuing additional research and formulations of Blue Scorpion Venom.”

About Preveceutical

For more information about Preveceutical, please visit www.preveceutical.com, or follow us on Twitter: https://twitter.com/preveceuticals

On Behalf of the Board,

"Stephen Van Deventer"
President and CEO

This news release may contain forward-looking statements concerning future operations of Preveceutical Medical Inc. (the "Company"). All forward-looking statements concerning the Company's future plans and operations, including management's assessment of the Company's operational expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates or projections.

Sign up for the latest news and updates